These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15975002)

  • 1. Novel agents that potentially inhibit irinotecan-induced diarrhea.
    Yang X; Hu Z; Chan SY; Chan E; Goh BC; Duan W; Zhou S
    Curr Med Chem; 2005; 12(11):1343-58. PubMed ID: 15975002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
    Yang XX; Hu ZP; Xu AL; Duan W; Zhu YZ; Huang M; Sheu FS; Zhang Q; Bian JS; Chan E; Li X; Wang JC; Zhou SF
    J Pharmacol Exp Ther; 2006 Oct; 319(1):82-104. PubMed ID: 16815871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.
    Yang XX; Hu ZP; Chan SY; Duan W; Ho PC; Boelsterli UA; Ng KY; Chan E; Bian JS; Chen YZ; Huang M; Zhou SF
    Curr Drug Metab; 2006 May; 7(4):431-55. PubMed ID: 16724931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
    Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
    Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats.
    Takasuna K; Kasai Y; Kitano Y; Mori K; Kobayashi R; Hagiwara T; Kakihata K; Hirohashi M; Nomura M; Nagai E
    Jpn J Cancer Res; 1995 Oct; 86(10):978-84. PubMed ID: 7493918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.
    Takasuna K; Hagiwara T; Watanabe K; Onose S; Yoshida S; Kumazawa E; Nagai E; Kamataki T
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):494-503. PubMed ID: 16437251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.
    Ikuno N; Soda H; Watanabe M; Oka M
    J Natl Cancer Inst; 1995 Dec; 87(24):1876-83. PubMed ID: 7494232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal toxicity or irinotecan.
    Hecht JR
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):72-8. PubMed ID: 9726096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea.
    Ikegami T; Ha L; Arimori K; Latham P; Kobayashi K; Ceryak S; Matsuzaki Y; Bouscarel B
    Cancer Res; 2002 Jan; 62(1):179-87. PubMed ID: 11782376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver.
    Tobin PJ; Hong Y; Seale JP; Rivory LP; McLachlan AJ
    J Pharm Pharmacol; 2005 Jan; 57(1):39-45. PubMed ID: 15638991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.
    Kurita A; Kado S; Matsumoto T; Asakawa N; Kaneda N; Kato I; Uchida K; Onoue M; Yokokura T
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):201-13. PubMed ID: 20354702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase.
    Rivory LP; Bowles MR; Robert J; Pond SM
    Biochem Pharmacol; 1996 Oct; 52(7):1103-11. PubMed ID: 8831730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion.
    Kurita A; Kado S; Kaneda N; Onoue M; Hashimoto S; Yokokura T
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):349-60. PubMed ID: 12904895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
    Kudoh S; Fukuoka M; Masuda N; Yoshikawa A; Kusunoki Y; Matsui K; Negoro S; Takifuji N; Nakagawa K; Hirashima T
    Jpn J Cancer Res; 1995 Apr; 86(4):406-13. PubMed ID: 7775263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38.
    Sasaki Y; Hakusui H; Mizuno S; Morita M; Miya T; Eguchi K; Shinkai T; Tamura T; Ohe Y; Saijo N
    Jpn J Cancer Res; 1995 Jan; 86(1):101-10. PubMed ID: 7737901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats.
    Kurita A; Kado S; Kaneda N; Onoue M; Hashimoto S; Yokokura T
    Cancer Chemother Pharmacol; 2000; 46(3):211-20. PubMed ID: 11021738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients.
    Takeda Y; Kobayashi K; Akiyama Y; Soma T; Handa S; Kudoh S; Kudo K
    Int J Cancer; 2001 Apr; 92(2):269-75. PubMed ID: 11291056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
    Gupta E; Lestingi TM; Mick R; Ramirez J; Vokes EE; Ratain MJ
    Cancer Res; 1994 Jul; 54(14):3723-5. PubMed ID: 8033091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity.
    Wadkins RM; Hyatt JL; Yoon KJ; Morton CL; Lee RE; Damodaran K; Beroza P; Danks MK; Potter PM
    Mol Pharmacol; 2004 Jun; 65(6):1336-43. PubMed ID: 15155827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes.
    Hanioka N; Ozawa S; Jinno H; Tanaka-Kagawa T; Nishimura T; Ando M; Sawada Ji J
    Drug Metab Dispos; 2002 Apr; 30(4):391-6. PubMed ID: 11901092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.